Urease inhibitory activities of β-boswellic acid derivatives
© Golbabaei et al.; licensee BioMed Central Ltd. 2013
Received: 27 September 2012
Accepted: 28 December 2012
Published: 2 January 2013
Background and the purpose of the study
Boswellia carterii have been used in traditional medicine for many years for management different gastrointestinal disorders. In this study, we wish to report urease inhibitory activity of four isolated compound of boswellic acid derivative.
4 pentacyclic triterpenoid acids were isolated from Boswellia carterii and identified by NMR and Mass spectroscopic analysis (compounds 1, 3-O-acetyl-9,11-dehydro-β-boswellic acid; 2, 3-O-acetyl-11-hydroxy-β-boswellic acid; 3. 3-O- acetyl-11-keto-β-boswellic acid and 4, 11-keto-β-boswellic acid. Their inhibitory activity on Jack bean urease were evaluated. Docking and pharmacophore analysis using AutoDock 4.2 and Ligandscout 3.03 programs were also performed to explain possible mechanism of interaction between isolated compounds and urease enzyme.
It was found that compound 1 has the strongest inhibitory activity against Jack bean urease (IC50 = 6.27 ± 0.03 μM), compared with thiourea as a standard inhibitor (IC50 = 21.1 ± 0.3 μM).
The inhibition potency is probably due to the formation of appropriate hydrogen bonds and hydrophobic interactions between the investigated compounds and urease enzyme active site and confirms its traditional usage.
KeywordsBoswellia carterii Urease inhibitor Boswellic acid Docking Autodock
Inhibition of enzymes by natural products which are proven to be the source of therapeutic agents, have increasingly attracted the interests of scientists as a valuable strategy in drug discovery. Boswellia carterii is widely distributed in the Indian subcontinent and Africa. The gum exudates of Boswellia spp. comprise of several pentacyclic triterpenoid acids, which are known as boswellic acids (BA’s) and reported to have different biological activities. Their ability to induce apoptosis choose them as potent compounds in treatment of colon, prostate and breast cancers [1–7] and a broad range of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease [8–11]. Also their inhibitory effect through topoisomerase I and II has been reported .
In addition, a number of extracted organic acids of this plant show other biological activities such as inhibition of peptic ulcer formation, probably by increasing the gastric mucosal resistance which its exact molecular mechanism is still not clear. In the recent report, it was shown that methanolic extract of B. carterii has urease inhibition activity [13, 14].
Enzyme inhibition has already led to the discovery of the wide variety of useful drugs in the treatment of several diseases. It is found that Helicobacter pylori infection is the main cause of gastritis, peptic ulcer disease and gastric cancers [15, 16].
Urease of H. pylori producing abundant amounts of ammonia (10–15% of total proteins by weight), make the growth and survival of bacteria possible, by increasing the pH of environment . Therefore, it plays the major role in gastric diseases. Accordingly, urease inhibition has recently attracted much attention in pharmaceutical applications and discovery of potent anti-ulcer drugs. H. pylori has become resistant to many antibiotics, thus introducing new agents, like natural urease inhibitors, is of special importance. In addition, urease activity not only participates in the formation of kidney stones , but also involves in the development of urolithiasis, pyelonephritis, hepatic encephalopathy .
Throughout our work to search for natural urease inhibitor’s compounds from medicinal plants, we now report the isolation of four derivatives of boswellic acids to test their inhibitory activities through Jack bean urease. We employed Jack bean urease instead of bacteria’s one because it was previously found out that the mechanism and kinetics of inhibition for bacteria urease and Jack bean urease are comparable .
Molecular docking and simulation studies improve the reliability, accuracy of biological test, and show possible interactions between molecules and their target receptors. So the extracted compounds were subjected to molecular docking for better recognition of their interaction with urease.
Material and methods
Jack bean urease (EC 18.104.22.168 from Fluka Co, Switzerland), thiourea and all other chemicals used were of analytical grade (Merck Co, Germany). All solutions were prepared in MilliQ (Millipore, USA) water.
Preparation of extract
An earlier report claimed that acetyl-keto-β-boswellic acid could not be separated from a mixture of acetyl-β-boswellic acid and acetyl keto-β-boswellic acid by any of the chemical methods, such as ketal formation  or semi-carbazide formation. In another method, methanol was found to be the most appropriate solvent for extraction, and used for simultaneous quantitative estimation of major BA’s from Boswellia spp.
In this research, solvent-solvent extraction, thin-layer (TLC) and column chromatography were performed to isolate the main active constituent of B. carterii. A total of 10 g of oleo-gum resin was grounded. Of this, extraction performed in 100 ml methanol three times. After filtration, the extract was concentrated and solvent was removed. KOH 2% was added to separate the acidic fraction and extraction was performed by ethyl acetate five times. In the next step, the aqueous phase was acidified with HCl 2%, and previous step was repeated. Then the organic phase washed with distilled water to obtain fractions containing BA’s compounds. Liquid chromatography was used to obtain related derivatives in organic fraction. The organic layers were dried, filtered and concentrated under vacuum on a rotary evaporator. Liquid chromatography of 5 g of sample which dissolve in chloroform is performed on 100 g of silica gel 60 (0.063 - 0.2 mm). Solvent partitioning of the crude extracts was used to divide the extract into eight fractions with different polarities. The fractions were combined based on similarity of the chemical composition determined by TLC analysis.
For urease inhibition assays after addition of phosphate buffer pH = 6.8, sonication was performed for 3 min, followed by centrifugation and evaluating absorbance of upper solution in λ = 278 nm which is attributed to the urease. By using following equation A = λbc, where c is the concentration of solution (mol/L), b the Length of the UV cell, we can calculate the concentration of initially urease solution in this way. After appropriate dilution, the concentration of enzyme solution adjusted 2 mg/ml.
The assay mixture, containing 50 μl (2 mg/ml) of Jack-bean urease and 100 μl of different concentration of test compounds, which were dissolved in ethanol 20% previously, was added to 850 μl of 25mM urea and pre-incubated for 0.5 h in water bath at 37°C. The urease reaction was stopped after 30 min incubation by following procedure.
Urease activity was determined by measuring ammonia production using the indophenol method as described by Weatherburn . After pre-incubation, 500 μl of phenol reagent (1% w/v phenol and 0.005% w/v sodium nitroprusside) and 500 μl of alkali reagent (1% w/v NaOH and 0.075% active chloride NaOCl) were added to 100 μl of incubation mixture and kept at 37°C for 30 min.
The absorbance was measured at 625 nm. All experiments were performed in triplicate in a final volume of 1 ml, and thiourea was used as a standard urease inhibitors. Percentage inhibitions were calculated using the formula (100 – (OD sample / OD control) × 100).
The concentration that provokes an inhibition halfway between the minimum and maximum response of each compound (relative IC50) was determined by monitoring the inhibition effect of various concentrations of compounds in the assay. The IC50 values were then calculated using GraphPad Prism 5 software.
The newly compounds were subjected for molecular docking. To validate observed activities and designing new inhibitors based on choosing the appropriate pharmacophore molecular docking was performed using AutoDock 4.2 along with AutoDockTools 1.4.5 using Lamarckian genetic algorithm on PDB structure (3LA4) http://www.pdb.org with resolution of 2°A .
In the present study, non-standard protein residues (KCX and CME) and the metal ions were included in the binding site specification. The docking calculations adopted in this work yield favorable orientations of ligands in a receptor. The graphical user interface ADT was employed to set up the enzymes: all hydrogen calculated and nonpolar hydrogens were merged to carbons. For determination of pharmacophore, Ligandscout 3.03 program was used .
Four potent inhibitors have sketched by Marvin sketch applet (Marvin package, Chemaxon company). Then adding polar hydrogens and rotatable bonds were done with Openbabel and AutodockTools, respectively [24, 25]. Docking with a maximum number of 25 × 106 energy evaluations were performed. After clustering analysis, conformation with the most favorable binding energy was selected.
Result and discussion
Plants are the important source of new drug developments. Current study presents an investigation on urease inhibition of four isolated compounds from B. carterii which has been numbered as medicinal plant and had been used in stomach and colon disorders [26, 27], on the other hand, detection of urease inhibitors, have been regarded as targets for new anti-ulcer drugs.
Percent of inhibition, IC 50 and ΔGº of four isolated boswellic acids derivatives
Percent of inhibition (50 μg/ml)
IC50 ± S.E.M (μM)
6.27 ± 0.037
9.21 ± 0.069
16.34 ± 0.063
85.23 ± 0.065
21.10 ± 0.3
Out of four BA’s tested for their urease inhibitory activity, compound 4 was the only weakly active (IC50 = 85.23 ± 0.06 μM) and compound 1 (IC50 = 6.27 ± 0.03 μM) was found to be the most potent compound, compared to the standard inhibitor (thiourea, IC50 = 21.1 ± 0.3 μM). In this series, compounds 2 and 3 (IC50 = 9.21 ± 0.06, 16.34 ± 0.06 μM, respectively) are exhibited remarkable inhibition toward urease.
As it has shown, the enhanced percentage of urease inhibitory activity of compounds 1, 2 and 4 with 60.5, 56.2 and 39.1%, respectively, compared to the structurally related compound 3 (37.4%) may either be due to the presence of methyl group and hydrophobic interaction of them with adjacent amino acids. This interaction becomes lower in the case of compound 3 because of steric factors. This phenomenon is depicted clearly in Figure 5.
As it has shown in Figure 5, for compound 3, due to hydrogen bonding between oxygen of carboxyl group and Arg 368 and Gln 364, conformational locking happened, which possibly make the approach of the compound difficult towards the enzyme’s binding site and results in a sharp decline in inhibitory potential as compared to compound 4 (Figure 6). In another word, substitution at ortho position of C ring with different groups such as hydroxyl and ketone result to diminish of the inhibition potency. This effect explains the lower hydrophobic interaction between methyl group and amino acids present at interacting site.
Besides, presence of three kinds of hydrogen bonds formed by the carboxyl group of compound 1, two kinds of hydrogen bonds in compound 2 and one kind in compound 4 with respective amino acids in the hydrophobic pocket can explain their percent of inhibition activity order against urease (Table 1). For compound 3, despite the existence of four hydrogen bond’s percent of inhibition decrease dramatically. This observation can be explained by existing steric hindrance, which prevents the compound to interact with the hydrophobic site appropriately.
In this research isolated compounds from B. carterii has been tested against urease, which may confirm its potential traditional use for stomach problems. Based on the above study, we can preliminarily conclude that the substituted C ring of BA’s may result to decreased inhibition concentration compared with the reference inhibitor thiourea. In addition, hydrophobic interactions between methyl group of compounds and near residues play an important role in the inhibition. This observation can be applied to the development of new antiulcer agents.
This project was supported by grants from the Research Council of Tehran University of Medical Sciences and Iran National Science Foundation.
- Han RJ: Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells. 1994, 12: 53-63. 10.1002/stem.5530120110.View ArticlePubMedGoogle Scholar
- Bhushan S, Kumar A, Malik F, Andotra SS, Sethi VK, Kaur IP, Taneja SC, Qazi GN, Singh JJ: A triterpenediol from boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis. 2007, 12: 1911-1926. 10.1007/s10495-007-0105-5.View ArticlePubMedGoogle Scholar
- Janssen G, Bode U, Breu H, Dohrn B, Engelbrecht V, Gobel UJ: Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr. 2000, 212: 189-195. 10.1055/s-2000-9676.View ArticlePubMedGoogle Scholar
- Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker DK: Boswellic acids inhibit glioma growth: a new treatment option?. J Neurooncol. 2000, 46: 97-103. 10.1023/A:1006387010528.View ArticlePubMedGoogle Scholar
- Glaser T, Winter S, Groscurth P, Safayhi H, Sailer E-R, Ammon HPT, Schabet M, Weller MJ: Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer. 1999, 80: 756-765. 10.1038/sj.bjc.6690419.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu JJ, Nilsson A, Oredsson S, Badmaev V, Zhao WZ, Duan R-D: Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. J Carcinogenesis. 2002, 23: 2087-2093. 10.1093/carcin/23.12.2087.View ArticleGoogle Scholar
- Hoernlein RF, Orlikowsky T, Zehrer C, Niethammer D, Sailer ER, Simmet T, Dannecker GE, Ammon HP: Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Phamacol Exp Ther. 1999, 288: 613-619.Google Scholar
- Shen Y, Hu Y, Chen B, Yao SJ: Screening of enzyme inhibitors from traditional Chinese medicine. Comb chem high throughput screening. 2010, 13: 885-899. 10.2174/138620710793360239.View ArticleGoogle Scholar
- Frank MB, Yang Q, Osban J, Azzarello JT, Saban MR, Saban R, Ashley RA, Welter JC, Fung K, Lin H-KJ: Frankincense oil derived from boswellia carteri induces tumor cell specific cytotoxicity. BMC Complementary Altern Med. 2009, 9: 6-17. 10.1186/1472-6882-9-6.View ArticleGoogle Scholar
- Akihisa T, Tabata K, Banno N, Tokuda H, Nishihara R, Nakamura Y, Kimura Y, Yasukawa K, Suzuki TJ: Cancer chemopreventive effects and cytotoxic activities of the triterpene acids from the resin of boswellia carteri. Biol Pharm Bull. 2006, 29: 1976-1979. 10.1248/bpb.29.1976.View ArticlePubMedGoogle Scholar
- Vivek R, Yadav L, Prasad S, Sung B, Juri G, Gelovani J, Guha S, Krishnan S: Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer. 2012, 130: 2176-2184. 10.1002/ijc.26251.View ArticleGoogle Scholar
- Syrovets T, Buchele B, Gedig E, Slupsky JR, Simmet TJ: Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II alpha. Mol Pharmacol. 2000, 58: 71-81.PubMedGoogle Scholar
- Singh S, Khajuria A, Taneja SC, Khajuria RK, Singh J, Johri RK, Qazi GNJ: The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from boswellia serrata, in rats. Phytomedicine. 2008, 15: 408-415. 10.1016/j.phymed.2008.02.017.View ArticlePubMedGoogle Scholar
- Biglar M, Soltani K, Bazl R, Amanlou M: A preliminary investigation of the jack-bean urease inhibition by randomly selected traditional used herbal medicine. IJPR. 2012, 11: 831-837.PubMed CentralPubMedGoogle Scholar
- Devesa SS, Blot WJ, Fraumeni JF: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. J Cancer. 1998, 83: 2049-2053. 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2.View ArticleGoogle Scholar
- Howson CP, Hiyama T, Wynder EL: The decline of gastric cancer: epidemiology of an unplanned triumph. J Epidemiol Rev. 1986, 8: 1-27.Google Scholar
- Ha N-C, Oh S-T, Sung JY, Cha KA, Lee MH, Oh BH: Supramolecular assembly and acid resistance of helicobacter pylori urease. J Nat Struct Biol. 2001, 8: 505-509. 10.1038/88563.View ArticleGoogle Scholar
- Mobley HLT, Hausinger RP: Microbial ureases: significance, regulation, and molecular characterization. J Microbial Rev. 1989, 53: 85-108.Google Scholar
- Lodhi MA, Hussain J, Abbasi MA, Jassbi AR, Choudhary MI, Ahmad VJ: A new bacillus pasteurii urease inhibitor from euphorbia decipiens. J Enzyme Inhib Med Chem. 2006, 21: 531-535. 10.1080/14756360600586072.View ArticlePubMedGoogle Scholar
- Ciurli S, Benini S, Rypniewski WR, Wilson KS, Miletti S, Mangani S: The complex of Bacillus pasteurii urease with acetohydroxamate anion from X-ray data at 1.55 Å resolution. J Coord Chem Rev. 1999, 190: 331-355.View ArticleGoogle Scholar
- Magerlein BJ, Levin RHJ: Chemical studies with 11-oxygenated steroids. V. 3α,20β-Dihydroxypregnan-11-one 11-ethylene ketal. J Am Chem Soc. 1955, 77: 1904-View ArticleGoogle Scholar
- Azizian H, Nabati F, Sharifi A, Siavoshi F, Mahdavi M, Amanlou M: Large-scale virtual screening for the identification of new helicobacter pylori urease inhibitor scaffolds. J Mol Model. 2011, 18: 2917-2927.View ArticlePubMedGoogle Scholar
- Wolber G, Langer T: LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005, 45: 160-169. 10.1021/ci049885e.View ArticlePubMedGoogle Scholar
- Wolber G, Dornhofer AA, Langer T: Efficient overlay of small organic molecules using 3D pharmacophores. J Comput Aided Mol Des. 2007, 20: 773-788. 10.1007/s10822-006-9078-7.View ArticleGoogle Scholar
- Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Distributed automated docking of flexible ligands to proteins: parallel applications of autodock 2.4. J Comput Chem. 1996, 19: 1639-1662.View ArticleGoogle Scholar
- Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges RZ: Therapy of active crohn disease with boswellia serrata extract H 15. Gastroenterol. 2001, 39: 11-17. 10.1055/s-2001-10708.View ArticleGoogle Scholar
- Gupta I, Parihar A, Malhotra P, Singh GB, Lüdtke R, Safayhi H, Ammon HP: Boswellia serrata gum resin in patients with ulcerative colitis. J Eur Med Res. 1997, 2: 37-43.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.